The global hemostats market size was estimated to be US$ 3.3 Billion in 2022 and is expected to reach US$ 5.9 Billion by 2032 at a CAGR of 6%.
Hemostatis is a process for prevention, stop bleeding or containing blood within the blood vessel. Hemostat are the surgical devices used in wide range of surgical procedures to control bleeding. The rapid increase in the number of people affected with chronic disorders such as cardiovascular, spinal, respiratory and lifestyle disorders such as diabetics, and obesity has increased the number of surgeries across the globe, thereby fueling the demand for wound closure and wound sealant products and devices.
The prevalence of diabetes among adults over 18 years of age has increased by approximately 4.0% since 1980 globally as per statistics published by World Health Organization. In the United States alone, approximately 10.5% of the population is suffering from diabetes and approximately 34.5% of the United States adult population have prediabetes based on the data published by the Centers for Disease Control and Prevention, the U.S. Depart of Health and Human Sciences. This has in turn increased the number of kidney failure, heart attacks, stroke and lower limb amputation surgeries, and has created a significant demand for wound closure product and devices such as hemostats.
The report titled “Hemostat Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global hemostat market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, security & exchange overview, research & development activities, production facilities, product portfolio, employee strength, and key executive, for all the major players operating in the market. For instance, Pfizer Inc. reported revenue of US$ 51.8 Billion in 2019 and the segment and geographic analysis of the company indicates that Biopharma business segment of the company dominated revenue in 2019 with the United States being the major revenue generating country.
The global hemostat market is segmented based on product type, formulation, application, end user, and geography. Based on product type, the global hemostat market is segmented into mechanical hemostat, thrombin-based hemostat, oxidized regenerated cellulose-based hemostat, combination hemostat, gelatin-based hemostat, collagen-based hemostat, and others. Based on formulation, the global hemostat market is segmented into matrix & gel hemostat, sheet & pad hemostat, sponge hemostat, and powder hemostat. Based on applications, the global hemostat market is segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, gynecological surgery, and other surgeries. Based on end user, the global hemostat market is segmented into hospitals, surgery centers, nursing homes, and others. Based on geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
Additionally, the study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the hemostat companies. Further, market share of prominent companies in the global hemostat market would also be estimated.
For instance, Pfizer Inc. operates through three business divisions namely Biopharma, Upjohn, and Consumer Healthcare. The Hemostats are delivered under Biopharma business division of the company with revenue contribution of US$ 39,419 Million in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the hemostat companies. Furthermore, the global hemostat market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the hemostat market business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global hemostat market arena.
Major players operating the global hemostat market include Baxter International Inc., B. Braun Melsungen AG, C. R. Bard, Inc., Ethicon, Inc. (Johnson & Johnson), GELITA MEDICAL, Integra LifeSciences Corporation, Marine Polymer Technologies, Inc., Pfizer Inc., Teleflex Incorporated, and Z-Medica, LLC.
Market Segmentation:
By Product type
By Formulation
By Application
By End user
By Geography
The hemostat market size is anticipated to reach US$ 5.9 billion by 2032.
The hemostat market is expected to rising at a CAGR of 6% from 2023 to 2032.
Hemostatis is a process for prevention, stop bleeding or containing blood within the blood vessel.
The hemostat market size size surpassed US$ 3.3 Billion in 2022.
Based on formulation, the hemostat market is segmented into matrix & gel hemostat, sheet & pad hemostat, sponge hemostat, and powder hemostat.
The rapid increase in the number of people affected with chronic disorders such as cardiovascular, spinal, respiratory and lifestyle disorders such as diabetics, and obesity has increased the number of surgeries across the globe, thereby fueling the demand for hemostat.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved